Active	Status	Sponsor type	Region	Phase	Filter
6 Active 3 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Beissert, Stefan
NCT06602219: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	2	220	Canada, Japan, US	LY4100511, Placebo	DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company	Plaque Psoriasis	07/25	08/25
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis	Completed	1	24	Europe, US	CDX-0159, barzolvolimab, Normal saline	Celldex Therapeutics	Prurigo Nodularis	07/23	07/23
Blümlein, Katharina
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Active, not recruiting	2/3	301	Europe, Japan, US, RoW	HZN-825 BID, Placebo, HZN-825 QD	Amgen, Horizon Therapeutics USA, Inc	Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic	09/25	09/25
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria	Active, not recruiting	2	208	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics	Chronic Spontaneous Urticaria	09/23	03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria	Active, not recruiting	2	196	Europe, US, RoW	barzolvolimab, CDX-0159, Matching Placebo	Celldex Therapeutics, Celldex Therapeutics, Inc.	Chronic Inducible Urticaria	06/24	09/25
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis	Completed	1	24	Europe, US	CDX-0159, barzolvolimab, Normal saline	Celldex Therapeutics	Prurigo Nodularis	07/23	07/23